A new technology at chemistry-biology interface for photocontrolled release of bioactive molecules in the brain <u>Camille Ruffier</u>¹, Emmanuel Ibarboure², Jean-Christophe Helbling¹, Maria-Florencia Angelo¹, Sébastien Marais⁴, Rémi Kinet⁵, Noel Pairault³, Benjamin Dehay⁵, Pierre Trifilieff¹, Nathan D. McClenaghan³, Sébastien Lecommandoux², Clémentine Bosch-Bouju¹ ¹ Univ. Bordeaux, INRAE, Bordeaux INP, Nutrineuro, UMR1286, FR-33000, Bordeaux, France ⁴ Univ. Bordeaux, CNRS, INSERM, INRAE, BIC, UAR3420, US4, FR-33000, Bordeaux, France ² Univ. Bordeaux, CNRS, Bordeaux INP, LCPO, ENSMAC, UMR5629, FR-33000, Bordeaux, France ⁵ Univ. Bordeaux, CNRS, IMN, UMR5293, FR-33000, Bordeaux, France ³ Univ. Bordeaux, CNRS, Bordeaux INP, ISM, UMR5255, F-33000, Bordeaux, France **CONTEXT OBJECTIVE What's Innovative?** Light-triggered delivery • Brain disorders affect 1 in 3 people worldwide. To develop photosensitive polymersomes that system for specific drug • The blood-brain barrier (BBB) limits drug delivery to the brain. enable local delivery of biomolecules to the delivery to the brain. • Light-based tools (e.g., optogenetics) allow precise brain control but lack clinical use. **brain** through **light** activation, precisely Combines polymersomes • **Polymersomes** offer stable, efficient drug delivery. controlled in time, space and concentration. with stimulation precision Q PRINCIPLE OF THE NEUROTECHNOLOGY **DRUG DELIVERY SYSTEM NEUROSTIMULATION To control the release** of molecules **in time** and **To control the concentration** of encapsulated molecules **Key Features:** space using an optical fiber Stimuli: **Inverse Emulsion-Photosensitive polymersomes** Light by optical fiber Centrifugation¹ Polymersomes with optical fiber Target: Deep brain structures System: Posm Photosensitive biocompatible Photocleavable dyes + bioactive compounds + 300 mosm sucrose toluene A2. Interface w/o polymersomes **Precision**: Time and space Therapeutic scope: glucose 300 mosm in water Targets multiple brain diseases, including ¹Peyret, A., (2017), Angewandte oly(butadiene)-b-poly(ethyleneoxi glioblastoma **平 RESULTS** 1-PHOTOSENSITIVE POLYMERSOMES DESIGN 4-PHOTOSTIMULATION OF POLYMERSOMES IN BRAIN SLICES **Calcein-loaded Size distributions** $\underline{\lambda_{\text{exc}}}$ = 488 nm **✓** Only photostimulation of CNQX-loaded Mean = 8.27polymersomes leads to CNQX release SEM = 0.14and suppression of excitatory potentials PDI = 0.36_N__C00_ N = 12650 10 20 30 40 P < 0,0001 Diameter (µm) **✓** Physiological osmolarity **✓** No toxic solvents **✓** Small size 2-PHOTORELEASE OF POLYMERSOMES' CONTENTS IN SOLUTION Rupture of calcein-loaded polymersomes - - - + -Base Post Base Post Base Post Polym. with CNQX - - + - + Is the released CNQX concentration equivalent to the initially loaded dose? Polym. illumination away from recording site \checkmark 10 μ M in bath: complete block $\lambda_{\rm exc}$ = 488 nm **✓** 100 µM local: Selective rupture of calcein-loaded Rupture time distribution polymersomes in time and space N = 41Mean = 4s5-ASSESSMENT OF BIOAVAILABILITY AND BIOSAFETY OF POLYMERSOMES In Vivo imaging of polymersomes 0 10 20 30 $\lambda_{\rm exc}$ = 488 nm Time (s) MTT viability test Release time (s) **✓** Controlled release BE(2)-M17 human cell lines. N = 12 per treatment 3-ENCAPSULATION OF CNQX (100 μM) IN POLYMERSOMES **CNQX** = A blocker of neuronal transmission (glutamate AMPA receptor antagonist) 0 5 10 15 20 Polym. Cal. CNQX To monitor and validate polymersome AMPA-mediated synaptic excitatory currents release by electrophysiology. 0.0 1.5 3.0 6.0 12.0 30.0 To counteract invasion of neuronal 0.2 mV 20 ms Concentration (µg/mL) networks by glioblastoma cells.² ² Venkataramani, V., et al., (2022), Cell, PMID: 35914528 **✓** No strong effect on cell viability — Without CNQX — - With CNQX Mean = 8.27 Mean = 7.93 S N = 52 N = 41 **✓** Good bioavailability **✓** Persistent fluorescence at 21d SEM = 0.14 SEM = 0.14 $\frac{6}{5}$ PDI = 0.36 PDI = 0.39 N = 1265 N = 1218KEY MESSAGE & NEXT STEPS Traditionnal Approach Our Neurotechnolog 0 10 20 30 40 Systemic/Diffuse Brain targeting Highly Precise **✓** No impact on photoactivation properties On-demand None Partial Targeted/Localized **BBB Bypass FUNDING** >>> Next step: Implementation in a glioblastoma model Grand Programme de Recherche BRAIN_2030 Grand Programme de Recherche BRAIN_2030 Grand Programme de BORDEAUX De BORDEAUX FONDATION MEDISITE DE GRAND FORDEAUX FONDATION MEDISITE DE GRAND FORDEAUX Figures created using Biorender and ChemDraw